Drugs / CMK389
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04836858 | Apr 2021 → Jul 2022 | atopic eczema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04064242 | Sep 2020 → Sep 2023 | pulmonary sarcoidosis | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMK389 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04836858 ↗ |
| Route | Intravenous | “CMK389 10 mg/kg i.v. every 4 weeks for a total of 4 doses” NCT04064242 ↗ |